Karen L Reckamp1, Marianna Koczywas1, Mihaela C Cristea1, Jonathan E Dowell2, He-Jing Wang3, Brian K Gardner4, Ginger L Milne5, Robert A Figlin6, Michael C Fishbein7, Robert M Elashoff3, Steven M Dubinett8. 1. Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. 2. Department of Medicine, Veterans Affairs North Texas Healthcare System, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Department of Biomathematics, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 4. Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 5. Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee. 6. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. 7. Department of Pathology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 8. Departments of Medicine and Pathology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Abstract
BACKGROUND:Cyclooxygenase 2 (COX-2)-dependent signaling represents a potential mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. This is mediated in part through an EGFR-independent activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) by prostaglandin E2 (PGE2). PGE2 promotes downregulation of E cadherin and epithelial to mesenchymal transition. The current study investigated EGFR and COX-2 inhibition in patients with non-small cell lung cancer (NSCLC) and elevated baseline urinary metabolite of PGE2 (PGEM). METHODS:Patients with stage IIIB/IV (AJCC 6th edition) NSCLC who progressed after at least 1 line of therapy or refused standard chemotherapy were randomized to receive erlotinib and celecoxib versus erlotinib and placebo. The primary endpoint was progression-free survival (PFS) with 80% power to detect a 50% improvement with a 1-sided significance level of .2 in the intent-to-treat and elevated baseline PGEM populations. Secondary endpoints included response rate, overall survival, and evaluation of molecular markers to assess targeting COX-2-related pathways and evaluate EGFR tyrosine kinase inhibitor resistance. RESULTS: A total of 107 patients were enrolled with comparable baseline characteristics. Among the patients treated with celecoxib, those with wild-type EGFR were found to have an increased PFS (3.2 months vs 1.8 months; P = .03). PFS was numerically improved among patients in the intent-to-treat group who received erlotinib and celecoxib compared with those treated with erlotinib and placebo (5.4 months vs 3.5 months; P = .33) and was increased in patients in the erlotinib and celecoxib arm with elevated baseline PGEM (5.4 months vs 2.2 months; P = .15). Adverse events were similar in both treatment arms. CONCLUSIONS: The combination of erlotinib and celecoxib did not appear to improve outcomes in an unselected population, but selection by elevated baseline PGEM led to an increase in PFS with this combination. Patients with EGFR wild-type status may benefit from the combination of erlotinib and celecoxib.
RCT Entities:
BACKGROUND:Cyclooxygenase 2 (COX-2)-dependent signaling represents a potential mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. This is mediated in part through an EGFR-independent activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) by prostaglandin E2 (PGE2). PGE2 promotes downregulation of E cadherin and epithelial to mesenchymal transition. The current study investigated EGFR and COX-2 inhibition in patients with non-small cell lung cancer (NSCLC) and elevated baseline urinary metabolite of PGE2 (PGEM). METHODS:Patients with stage IIIB/IV (AJCC 6th edition) NSCLC who progressed after at least 1 line of therapy or refused standard chemotherapy were randomized to receive erlotinib and celecoxib versus erlotinib and placebo. The primary endpoint was progression-free survival (PFS) with 80% power to detect a 50% improvement with a 1-sided significance level of .2 in the intent-to-treat and elevated baseline PGEM populations. Secondary endpoints included response rate, overall survival, and evaluation of molecular markers to assess targeting COX-2-related pathways and evaluate EGFR tyrosine kinase inhibitor resistance. RESULTS: A total of 107 patients were enrolled with comparable baseline characteristics. Among the patients treated with celecoxib, those with wild-type EGFR were found to have an increased PFS (3.2 months vs 1.8 months; P = .03). PFS was numerically improved among patients in the intent-to-treat group who received erlotinib and celecoxib compared with those treated with erlotinib and placebo (5.4 months vs 3.5 months; P = .33) and was increased in patients in the erlotinib and celecoxib arm with elevated baseline PGEM (5.4 months vs 2.2 months; P = .15). Adverse events were similar in both treatment arms. CONCLUSIONS: The combination of erlotinib and celecoxib did not appear to improve outcomes in an unselected population, but selection by elevated baseline PGEM led to an increase in PFS with this combination. Patients with EGFR wild-type status may benefit from the combination of erlotinib and celecoxib.
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi Journal: Cancer Res Date: 1998-09-01 Impact factor: 12.701
Authors: Shirish M Gadgeel; John C Ruckdeschel; Elisabeth I Heath; Lance K Heilbrun; Raghu Venkatramanamoorthy; Antoinette Wozniak Journal: J Thorac Oncol Date: 2007-04 Impact factor: 15.609
Authors: Mariam Dohadwala; Seok-Chul Yang; Jie Luo; Sherven Sharma; Raj K Batra; Min Huang; Ying Lin; Lee Goodglick; Kostyantyn Krysan; Michael C Fishbein; Longsheng Hong; Chi Lai; Robert B Cameron; Robert M Gemmill; Harry A Drabkin; Steven M Dubinett Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701
Authors: Karen L Reckamp; Kostyantyn Krysan; Jason D Morrow; Ginger L Milne; Robert A Newman; Christopher Tucker; Robert M Elashoff; Steven M Dubinett; Robert A Figlin Journal: Clin Cancer Res Date: 2006-06-01 Impact factor: 12.531
Authors: Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544
Authors: Kostyantyn Krysan; Farrukh H Merchant; Li Zhu; Mariam Dohadwala; Jie Luo; Ying Lin; Nathalie Heuze-Vourc'h; Mehis Põld; David Seligson; David Chia; Lee Goodglick; Hejing Wang; Robert Strieter; Sherven Sharma; Steven Dubinett Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: Barbara J Gitlitz; Eric Bernstein; Edgardo S Santos; Greg A Otterson; Ginger Milne; Mary Syto; Francis Burrows; Sara Zaknoen Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609
Authors: Kostyantyn Krysan; Xiaoyan Cui; Brian K Gardner; Karen L Reckamp; Xiaoyan Wang; Longsheng Hong; Tonya C Walser; Nicole L Rodriguez; Paul C Pagano; Edward B Garon; John F Brothers; David Elashoff; Jay M Lee; Avrum E Spira; Sherven Sharma; Michael C Fishbein; Steven M Dubinett Journal: Am J Transl Res Date: 2013-08-15 Impact factor: 4.060